Journals
Publish with us
Publishing partnerships
About us
Blog
Canadian Respiratory Journal
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Canadian Respiratory Journal
/
2019
/
Article
/
Tab 3
/
Research Article
Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada
Table 3
Scenario analysis results: incremental cost and incremental effect.
Aerobika® device
No PEP/OPEP therapy
Total direct medical cost
$6,712.19
$8,835.71
Total QALYs
0.63
0.53
Cost savings
$2,123.52
QALY gained
0.1
Incremental cost-effectiveness ratio (ICER)
Aerobika® device is the dominant strategy